

MINUTE ENTRY
MILAZZO, J.
SEPTEMBER 5, 2019

JS-10: 03:55

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA

IN RE: TAXOTERE (DOCETAXEL)) MDL No. 16-2740
PRODUCTS LIABILITY LITIGATION)
) SECTION: "H" (5)
)
THIS DOCUMENT RELATES TO:)
Applies to: 16-17144 - Barbara Earnest

MOTION HEARING

Judge Jane Triche Milazzo presiding

LAW CLERK: SAMANTHA SCHOTT
COURT REPORTER: NICHELLE DRAKE
CASE MANAGER: ERIN MOULEDOUS
COUNSEL: See attached sign-in sheet

Court begins at 1:00 p.m.

The following Motions in Limine are argued by counsel and Orders rendered as set forth below:

MOTION *in Limine* to Preclude Any Comment or Argument That Dr. Carinder Is Responsible for Plaintiff's Condition (**R. Doc. 7653**) is **GRANTED IN PART & DENIED IN PART.**

MOTION *in Limine* to Preclude Testimony and Evidence Regarding Instances of Permanent Alopecia Among Those Prescribed Taxotere by Sanofi's Experts (**R. Doc. 7652**) is **GRANTED.**

MOTION *in Limine* to Preclude Testimony and Evidence Regarding Other Chemotherapy Medications or Medical Conditions That Purportedly Cause Permanent Hair Loss (**R. Doc. 7651**) is **GRANTED IN PART & DENIED IN PART.**

MOTION *in Limine* to Exclude Testimony and Argument That Taxotere Has Saved Lives (**R. Doc 7660**) is **GRANTED IN PART & DENIED IN PART.**

MOTION *in Limine* to Exclude Evidence and Argument Regarding Evaluations of Plaintiff by Formerly Retained Experts and Who Will Not Testify at Trial **(R. Doc. 8108)** is **GRANTED**.

First Omnibus MOTION *in Limine* **(R. Doc 7720)** is **DEFERRED** insofar as it addresses evidence of adverse event reports or other complaints involving patients other than plaintiff. All other arguments in Doc. 7720 remain pending before the Court.

The following motions are argued by counsel and taken under submission by the Court:

MOTION *in Limine* to Preclude Evidence of Unrelated Medical Conditions, Familial Medical History of Cancer, And Unrelated Medication Usage **(R. Doc 7647)**

MOTION *in Limine* to Preclude Any Comment or Argument That Taxol Would Have Enhanced the Severity Of Plaintiff's Neuropathy **(R. Doc 7649)**

Second Omnibus MOTION in Limine to Preclude Evidence or Argument Concerning Sanofi Promotional And/Or Marketing Materials Not Possessed Or Relied On By Plaintiff Or Her Prescribing Physician **(R. Doc 7657)**

Second Omnibus MOTION in Limine to Preclude Evidence or Argument Regarding Sanofi Sales Representatives **(R. Doc 7657)**

MOTION *in Limine* to Preclude Evidence or Argument Concerning Correspondence between DDMAC and Sanofi by Defendant **(R. Doc 7658)**

MOTION *in Limine* Excluding Improper Arguments or Suggestions Regarding FDA Approval **(R. Doc. 7659)**

MOTION *in Limine* to Preclude Evidence or Argument Regarding Foreign Labeling and Regulatory Actions **(R. Doc 7666)**


MOTION *in Limine* to Preclude Evidence and Argument that "Ongoing Alopecia" Data Observed in the Tax316 and GEICAM 9805 Clinical Trials Presents Evidence of "Persistent," "Permanent," or "Irreversible" Alopecia **(R. Doc 7668)**

MOTION *in Limine* to Preclude Evidence and Argument Regarding Shirley Ledlie and Any "Taxotears" or Other Third Party Advocacy or Communications Group or Group Members **(R. Doc 7670)**

MOTION *in Limine* to Preclude Evidence and Argument Regarding Company Conduct that Post-Dates Plaintiff's Chemotherapy Treatment **(R. Doc 7671)**

Order and Reasons to follow.

Court adjourned at 4:55 p.m.

A handwritten signature in black ink, consisting of a large, stylized 'J' or 'L' shape followed by a horizontal line and a small flourish.